Company: UPC
Filing Date: 2025-07-03
Form Type: 6-K
Source: 0001213900-25-061480
Chunk: 2

Company: Universe Pharmaceuticals INC
Filing Date: 2025-07-03
Form: 6-K
Chunk 2
---
,807 |     |        | 18.5 | % |
| Third-party products sales |     |                                    | 2,173,983 |     |         | 1,348,004 |     |        | 38.0 | % |     |         |  6,013,779 |     |         | 3,912,232 |     |        | 34.9 | % |
| Total                      |     | $                                  | 9,152,915 |     | $       | 5,988,385 |     |        | 34.6 | % |     | $       | 12,884,370 |     | $       | 9,515,039 |     |        | 26.2 | % |

<div align='center'>1</div>

Sales of the Company’s traditional Chinese medicine derivatives (“TCMD”) products increased by $108,341, or 1.6%, to $6,978,932 for the six months ended March 31, 2025, from $6,870,591 for the six months ended March 31, 2024. The increase in the sales of TCMD products was mainly attributable to the following: (i) a 1.8% increase in the average selling price of TCMD products by $0.02 per unit, to $1.15 per unit for the six months ended March 31, 2025, from $1.13 per unit for the six months ended March 31, 2024 due to a change in product mix; and partially offset by (ii) a 0.8% decrease in the sales volume of TCMD products of 46,941 units, to 6,050,384 units sold in the six months ended March 31, 2025, from 6,097,325 units sold in the six months ended March 31, 2024 due to a decline in customer demand.

Sales of third-party products decreased by $3,839,796, or 63.8%, to $2,173,983 for the six months ended March 31, 2025, from $6,013,779 for the six months ended March 31, 2024. The decrease in the sales of third-party products was mainly attributable to the following: (i) a 46.0% decrease in the average selling price of third-party products by $0.69 per unit, to $